Genetic factors partially explain the susceptibility of multiple sclerosis (MS) and might even relate to the clinical course. Still, many epidemiological studies point at an important role for environmental factors in MS. Smoking is one of the major candidates. In this review we provide an overview of the epidemiological studies on cigarette smoking and the association on MS risk and MS clinical course. In addition, we discuss the possible biological pathways that may influence neurological damage in MS. Moreover, the relation of smoking with other environmental MS risk factors will be addressed.
Introduction
Multiple sclerosis (MS) is regarded as a disease with a multifactorial aetiology, comprising genetic as well as environmental influence. Migration studies, geographical gradients and high rates of discordance in identical twins point to the influence of environmental factors interacting with genetics in determining disease susceptibility [1] . The landmark work of Kurtzke [2] showed that the MS risk declined twofold with migration from high-to low-risk areas which indicate that genetic factors can account for only a small proportion of geographical MS variety. This was also supported by others [3] , suggesting a role for a range of physical, chemical, biological and social environmental factors. Moreover, the evidence on the rising worldwide prevalence and increasing female to male ratio focuses the interest on environmental factors [4] .
The environmental risk factors implicated include sun exposure, vitamin D status, Epstein-Barr virus (EBV) infections and smoking. These factors combined can interact at different time points prior to and following the clinical onset of MS [5] . Cigarette smoking is emerging as one of the most postulated environmental risk factors linked to onset and clinical course of MS in genetically susceptible individuals [6, 7] . The history of the suggested association between MS and smoking goes back to the 1960s when few studies were performed, although these studies did not reach significance and analysed a large number of variables simultaneously [8, 9] .
In this review we aim to give an overview of the studies conducted on the association between smoking and MS susceptibility, and clinical course. In addition, we discuss the possible pathogenic role of smoking in MS and the related underlying mechanisms. Finally, we provide some arguments supporting, but also some challenging this association.
Cigarette smoking and risk of MS
Several retrospective and prospective studies have investigated the association between smoking and MS susceptibility. Table 1 gives a chronological summary of the key studies. One of the earliest papers to include smoking habit was an exploratory case-control study from Israel in 1965 [8] , where 241 MS patients were questioned about ever smoking prior to disease onset. The control group included 964 subjects individually matched to patients by age, sex and region of birth. They found significantly more previous smokers in the patient group (44% vs. 36%, p = 0.02). However, they did not correct for multiple comparisons.
It was not until the 1990s that two longitudinal studies among women in the United Kingdom [10, 11] showed that women who regularly smoked were found to have a higher risk of MS, although these findings were not significant. In the Oxford Family Planning Association Study, the incidence of MS in women who smoked ≥ 15 cigarettes per day was 1.8 (95% CI 0.8-3.6) times higher than in women who never smoked [10] . The Royal College of General Practitioners' Oral Contraception Study demonstrated comparable findings with the incidence of MS in women who smoked ≥15 cigarettes per day 1.4 (95% CI 0.9-2.2) times higher than never-smokers [11] . It should be noticed that both studies included only females and small number of incident cases of MS (63 and 114 respectively). Furthermore, assessing smoking history was a secondary question since both studies were conducted to investigate the possible relation of oral contraceptives and MS risk. A few years later a third prospective investigation was performed, which comprised more than 200,000 women participating in the Nurses' Health Study and Nurses' Health Study II and included 315 MS cases. This study showed a significant increase in MS risk among current smokers (OR 1.6, 95% CI 1.2-2.1). They also showed that the incidence of MS increased with the cumulative exposure to smoking [12] . The outcome was adjusted for age, latitude and ancestry. To be noted, they studied smoking behaviour 4 years prior to MS diagnosis. Next, the same study group investigated the association between MS and smoking in a nested case-control study based on the General Practice Research Database including 201 cases. They confirmed the higher MS risk for ever-smokers and current smokers (respectively OR 1.3, 95% CI 1.0-1.7 and OR 1.4, 95% CI 1.0-1.9) compared to never-smokers [13] . Another prospective study was presented by Carlens and colleagues [14] , who showed in a large cohort with 214 incident cases that the relative risk associated with ever-smoking was 1.9 (95% CI 1.4-2.6). Interestingly, this cohort included only males.
These results are consistent with several retrospective casecontrol studies [15] [16] [17] [18] [19] [20] , and population based surveys [21, 22] (Table 1) . Ghadirian et al. [15] showed in a case-control study of 200 incident MS cases from Montreal that ever-smoking was significantly associated with a higher MS risk (OR 1.6, 95% CI 1.0-2.4) and concurred with the stronger association for heavy smokers. Their analysis was based on reported cigarette smoking in the year prior to MS diagnosis and was adjusted for age, sex and education.
In a survey of the general population of Hordaland, Norway, including 22,312 individuals of which 86 had MS [21] , the risk of incident MS among current and ex-smokers was 1.8 (95% CI 1.1-2.9) times higher than the risk in subjects who had never smoked. Males had a higher risk ratio (RR 2.8) compared to females (RR 1.6), 95% CI were not given. The sex difference has also been demonstrated in a population based case-control study in Sweden. Hedström and colleagues [22] showed a higher OR for males compared to females (OR 1.8 vs. 1.4), next to a significant higher risk of MS for eversmokers (OR 1.5, 95% CI 1.3-1.8). In 2009 Rodriguez Regal et al. confirmed in a Spanish case-control study the association of cigarette smoking and MS. Surprisingly, in contrast to other studies they showed stronger effect among ex-smokers (OR 3.3, 95% CI 1.4-7.8) compared to current smokers (OR 2.0, 95% CI 1.2-3.3).
There are few studies, which did not show an association between MS and smoking. Some of these studies were subject to methodological limitations. Casetta et al. [23] performed a community-based case-control study in Ferrara, Italy. The MS population including 104 subjects was compared to 150 controls. Their study demonstrated no association between MS risk and smoking (results not shown). It is to be noted that they collected data on smoking and drinking in adolescence. In a recent case-control study in multiplex families [24] , we were not able to show an association of smoking and MS. This was possibly due to the higher genetic susceptibility in the multiplex families, which could obfuscate the role of smoking.
Recently it was demonstrated that exposure to environmental tobacco smoke is associated with an increased risk of MS. A French case-control study showed a positive association between parental smoking at home and early onset MS in their children [25] , suggesting a role for passive smoking. However, another study demonstrated no effect of maternal smoking during pregnancy on early onset MS in offspring [26] . Hedström and colleagues observed that never-smokers, who reported that they had been exposed to passive smoking, had an increased risk of developing MS compared to those who reported never to have been exposed (OR 1.3, 95% CI 1.1-1.5). The risk increased significantly with longer duration of exposure [27] .
Complementary to the studies investigating the association between cigarette smoking and MS susceptibility, a group in Austria studied the role of smoking after a first demyelinating event [28] . The clinically isolated syndrome (CIS) is the most common and recognised onset of MS. Most of the CIS patients with disseminated white-matter lesions on brain magnetic resonance imaging, and/or positive oligoclonal bands in the cerebrospinal fluid will develop clinically definite MS (CDMS) after a second relapse [29] . Di Pauli and colleagues [28] suggested that cigarette smoking was a risk factor for early conversion. They observed that a patient who smoked at onset of MS had a 1.8 fold increased risk of conversion to CDMS over 3 years compared with non-smokers (p = 0.008). It should be noted that there was a higher proportion of smokers in their CIS patients (46%) relative to the general population of Austria (29%), however this reference group was not age and sex matched.
Cigarette smoking and the clinical course of MS
Aggravation of MS symptoms shortly after starting to smoke has been reported in several early studies [9, [30] [31] [32] . The relationship between smoking and disease progression is still arguable. Some studies have suggested increased risk and others showed no effect. The variability in outcome of these studies can partly be explained by different measurements used for progression. Some studies investigated symptom aggravation or relapse rate; others used Kurtzke Expanded Disability Status Scale (EDSS) or MS Severity Scales (MSSS) to study disease disability in MS, but most of the studies focused on conversion to secondary progressive MS (SPMS).
An acute worsening of MS symptoms immediately following smoking was reported in a few clinical studies conducted more than 40 years ago [9] and it was confirmed in later investigations [32] . Emre and De Decker [32] showed that cigarette smoking causes a transient worsening of motor functioning. They used a battery of tests in 21 MS patients compared to healthy controls. In a prospective cohort study including 142 relapsing remitting MS (RRMS) patients, Pittas and colleagues showed no statistically significant associations between relapse rate and smoking behaviour. The hazard ratio (HR) for ever-smokers was 0.9 (95% CI 0.7-1.3) and for current smokers 1.0 (95% CI 0.6-1.6) [33] . There was also no dose related association. These analyses were adjusted for entry MSSS, follow-up time, gender, age at entry review, immunomodulatory treatment use, education level and month of review.
Interestingly, they demonstrated in the same study that increasing smoking pack years were positively associated with progression of clinical disability within the observation period, depicted in the MSSS and EDSS (p b 0.001). These effects persisted after further adjustment for factors like, time outside or in the sun in previous 6 months, serum 25(OH)D, total alcohol and fish intake [33] . A Swedish study estimated the effects of smoking in MS also using self-reported data on smoking habits in 122 incident cases. They assessed the MS disability using EDSS after a median disease duration of 6 years and showed that progressive disease disability was significantly more likely to occur in ever-smokers when compared with never-smokers (p= 0.006). Individuals with an early smoking start (≤15 years of age) scored higher compared with those starting smoking later (N15 years of age) (p= 0.005) or never-smokers (pb 0.001) [34] . Also the measurements by MSSS showed that ever-smokers have in average a significantly higher disability than never-smokers (median MSSS 5.2 versus 3.2, p = 0.042) [34] . And ever-smokers with early debut had in average a significantly higher disability than late starting smokers or never-smokers (median MSSS 6.5, 4.6 and 3.2; p = 0.011 and p = 0.002, respectively). However, another study assessing the impact of smoking on disability could not confirm these findings [35] . They compared prospectively collected clinical information with retrospectively collected data on smoking and reported that smoking was not related to time to reach the disability milestones of EDSS 4.0 or 6.0. Age at disease onset was the only variable associated with a shorter time to both EDSS milestones (pb 0.001). Though, they demonstrated that pack-years smoked after the onset of MS were significantly correlated with MSSS increase in the whole patient group (rho =−0.11, p =0.03) and in women (rho =−0.15, p =0.02).
In 2009 Healy and colleagues did also not found any association between smoking status and EDSS progression at the end of 2 and 5 years [36] . The percentage in whom disease progressed after 2 years was 23.3% in ever-smokers, 30.8% in ex-smokers, and 26.0% in never-smokers (p = 0.57, adjusted for baseline age, sex, disease duration, and treatment). They also studied progression in terms of brain MRI changes. They showed a significantly greater increase in T2-weighted lesion volume in current smokers compared with never-smokers (p = 0.02, adjusted for baseline age, sex, disease duration and disease course). In 2009 Zivadinov et al. [37] confirmed the association with MS clinical course, measuring disease progression by EDSS increase but also by MRI lesion volume and atrophy. They showed that ever-smokers had higher EDSS scores compared to never-smokers (median EDSS scores 3.0 and 2.5 respectively, p ≤ 0.001). They also demonstrated that mean number of contrast enhanced lesions on MRI for ever-smokers was significantly higher compared to never-smokers (mean 1.2 vs. 0.72 respectively, p b 0.001). Moreover, they showed that smoking was associated with increased lesion burden and greater atrophy (p b 0.001).
The major focus of studies investigating association between cigarette smoking and MS clinical course has been on the conversion to SPMS (Table 2 ). In 2005 a prospective cohort study using data from the General Practice Research Database showed that RRMS patients who smoked had N3 times higher risk of progression to SPMS [13] . This was studied in a small sample of 179 RRMS cases of which only 20 converted to SPMS during a mean follow-up time of 5.3 years. There were no data on duration or intensity of smoking [13] . Sundström and Nyström showed in 96 RRMS patients that the increased risk for secondary progression for ever-smokers compared with never-smokers is not due to differences in sex or age at disease onset (HR 2.4, 95% CI 1.0-6.0). The hazard ratio was borderline significant probably caused by the small numbers [34] . Also in another study was smoking associated with an increased risk of converting to a secondary progressive course within the cohort follow-up period, but this finding appeared partly due to smokers being of older age with longer disease durations [33] . In 2009 Healy and colleagues demonstrated in a much larger group of 891 patients an adverse influence of cigarette smoking for conversion of RRMS to SPMS [36] . During a mean (SD) follow-up of 3.3 (1.7) years, conversion to SPMS occurred in 72 patients. Current smokers converted faster from RRMS to SPMS compared to never-smokers (HR 2.5, 95% CI 1.4-4.4). This was not shown for ex-smokers (HR 1.1, 95% CI 0.6-1.8). Unlike previous mentioned positive studies, in 2007 Koch and his group found no association between cigarette smoking and progression to SPMS [35] . They compared prospectively collected clinical information with retrospectively collected data on smoking. The collection of data on smoking almost 20 years after recruitment of the patients could be a possible bias.
Taking all these studies into consideration, it is reasonable to conclude that smoking is a significant, but not powerful risk factor for MS onset and clinical course. A recently updated meta-analysis showed that smoking is associated with MS susceptibility in a conservative model with an RR of 1.5 (95% CI 1.4-1.6). However, the effect of smoking behaviour on the secondary progression of MS is less certain (RR 1.9, 95% CI 1.0-3.6) [38] .
Cigarette smoking and biological pathways
As discussed previously, various studies have been performed investigating cigarette smoke and MS; however, they only indicated an association. There is no evidence for a possible causal link between cigarette smoke and MS onset or clinical course. Nevertheless, if we assume that there is a possible link, then there are several hypotheses to be considered.
Cigarette smoke contains over 4500 of potentially toxic components, including tars, nicotine, carbon monoxide and other particles [39, 40] . Some components of cigarette smoke may have direct toxic effects on the central nervous system. Cigarette smoke exists of two phases: a particulate phase and a gaseous phase, both containing extremely high concentrations of free radicals [40] , which may cause axonal degeneration. The association between smoking and the risk of MS might be explained by the vulnerability of oligodendroglia, compared with astrocytes and microglia, to nitric oxide [41, 42] . Serum concentrations of cyanide, a component of cigarette smoke, and its main metabolite thiocyanate has long been known to cause demyelination in the CNS of animals [43] . As discussed earlier, smoking is suggested to be associated with MS clinical course. Progressive disease is characterised by the permanent neurological deficit, which is a result of axonal loss [44] . Exposure to nitric oxide has been shown to cause axonal degeneration or to block axonal conduction, especially in demyelinated axons [45] , suggesting a role for nitric oxide in secondary progressive MS.
Moreover, studies suggesting increased risk for developing MS [25, 27] support a direct role of tobacco components in the pathway.
Interestingly, a recent study in Sweden showed that tobacco smoking, but not the Swedish snuff, is associated with elevated risk for MS [22] . This suggests that the critical effects of smoking may be caused by irritation in the lungs or by increased incidence of respiratory infections leading to higher MS risk, which has already been suggested [46] . This pro-inflammatory effect of smoking is most likely triggered via toll-like receptors [47, 48] . (237) 1.1 (0.6-1.8)
Hazard ratio (HR); adjusted odds ratio (AOR); confidence interval (CI); relapsing remitting MS (RRMS), not reported (NR). a Cox Proportional Hazard Regression was performed by the studies. b Female/male ratio shown for the total cohort in the study, not limited to RRMS.
The pro-inflammatory effects of cigarette smoke have been studied in relation to the risk of cardiovascular disease and emphysema [49] . Cigarette smoke stimulates the influx and activation of neutrophils, monocytes and macrophages [50] . Both current and past smokers have higher fibrinogen levels, as a marker of inflammation, than nonsmokers, and these levels correlate with the number of cigarettes smoked per day [51, 52] . Cigarette smoke elevates peripheral blood leukocyte counts, [53, 54] , and is associated with important markers of inflammation like the C-reactive protein and IL-6 [55, 56] . Abnormalities in T-cell function [57, 58] , reduction in natural killer cells [59] and impairment of both humoral and cell-mediated immunity [59, 60] have been observed in smokers.
Several hypotheses based on biological mechanisms link cigarette smoking to MS and to other autoimmune diseases such as rheumatoid arthritis [61, 62] , systemic lupus erythematosus [63] , Graves' disease [61, 64] and inflammatory bowel disease [65] . This suggests either an immunomodulation or a pro-inflammatory influence on the immune system, including an increased pro-inflammatory cell activation in the lungs [66] or post-translational modifications of proteins which may break self-tolerance [67] , resulting in hypothetical autoimmune responses against antigens of the nervous system.
Another hypothesis could involve a direct effect of smoke components on microvascular blood flow and on the blood-brain barrier. Nicotine, a major component of cigarettes, has been shown to affect the integrity and function of the blood-brain barrier (BBB) [68] . This is important because leakage of BBB has been suggested as a factor in initiating the development of MS. This may be relevant to the recent report that cigarette smoking increases the risk of converting from CIS to CDMS [28] .
Additionally, cigarette smoking has anti-estrogenic effects as a result of producing inactive 2-hydroxy catechol estrogens [69, 70] . Women who are smokers undergo menopause earlier than nonsmokers [71] . Estrogens can affect the Th1/Th2 immune balance and also have either pro-or anti-inflammatory actions depending on their concentration [72] .
Discussion
The picture of how environmental exposures lead to autoimmune diseases in genetically predisposed individuals is becoming more comprehensive because of the numerous studies in different fields. We have discussed different studies investigating the association of smoking on MS onset and on MS clinical course. A recent metaanalysis demonstrated that cigarette smoking is important in determining MS susceptibility but the effect on disease progression is less certain [38] .
There are several limitations to be noted in these studies varying from recall, response rate, difference between responders and nonresponders, and possible misclassification in self-reported data. One of the most concerning disadvantages of all retrospective and questionnaire-based studies is that there is a possible recall bias. However, a recent study showed that participants reliably report smoking status over time [73] . But even when smoking habit is explored before MS onset, patients regularly confuse the time of MS onset with the time of diagnosis. This is sometimes difficult to determine even for the physicians. As a result, some outcome may relate to smoking after onset of MS. This issue is prevented in the prospective studies with data collection, in some studies at least 4 years prior to the first symptoms [12, 13] . Another potential methodological problem in case-control studies is the possible selection bias due to recruitment. Introducing prospective studies enables measuring cigarette smoke exposure more accurately without recall or report bias. Preferably, population based studies should be used. However, these surveys are expensive and collecting a statistically useful group size of incident cases is time consuming.
The heterogeneity in study design and outcome measures makes it difficult to combine the study results. The time of measurement differed in the studies; some studies examined the current smoking behaviour as a reflection of smoking prior to disease onset. There is evidence that smoking behaviour does not change significantly after diagnosis [20] , which implies that perhaps the difference in timing is not of special concern. Different studies showed a higher MS incidence with the cumulative exposure to smoking, however only few studies included the duration and quantity of smoking. It should also be noticed that the definition of the ever-smoker group is disputable. The composition of cigarettes over the years has changed and the quantities of inhaled toxins in low-tar and filtered cigarettes are unknown. Most of the studies focused on smoking did not consider passive exposure to tobacco smoke, which recently has been linked to MS [27] . Moreover, this exposure may vary considerably by geographic location given the local smoking laws. In addition, studying MS clinical course the different studies use a variety of parameters for assessment of MS progression, such as relapse rate [33] , EDSS or MSSS increase [35] and secondary progression [13, 34, 36] . These variations in measurements could account for some of the variability noted in the results.
Cigarette smoking cannot fully explain the latitude gradient of MS, the changes in risk with migration or the global variation in prevalence and sex differences [74] . However, it may partly explain the recently demonstrated increased female/male ratio in MS incidence [4, 75] . Moreover, investigating the association between smoking and MS can also be complicated by known and unknown confounders. There has been little attention for other health behaviours such as alcohol intake, body mass index or physical activity, although it has been suggested that MS patients are risk takers [76, 77] . These factors can influence the association between smoking cigarettes and MS. A well-known environmental risk factor for MS is infectious mononucleosis and the related anti-EBV antibodies. A recent study in healthy individuals showed that female gender, HLA-DR2 and cigarette smoking are each positively associated with EBV antibody levels [78] . This raises questions on the role of EBV in a possible common pathway associated with these factors [79] [80] [81] . Simon and colleagues examined the if the effect of smoking is independent from that of anti-EBNA titres, by comparing the association between ever-smoking and MS risk with and without adjustment for EBVtitres [20] . They demonstrated that the increased MS risk associated with ever smoking (OR 1.4, 95% CI 1.1-1.8) was no longer evident upon adjustment for anti-EBNA antibody titres (OR 1.1; 95% CI 0.8-1.4). In cases that had high anti-EBNA titres the risk of MS associated with ever smoking was increased (OR 1.7, 95% CI 1.1-2.6). Interestingly, the association between increasing anti-EBNA antibody titres and increased MS risk appeared to be approximately twofold greater among ever smokers compared to never smokers (OR 3.9, 95% CI 2.7-5.7 vs. OR 1.8, 95% CI 1.4-2.3), suggesting interaction between smoking and anti-EBNA titres (p for interaction = 0.001). They also showed that the increased risk of MS associated with smoking was independent of HLA-DR15 status, although there were implications of betweenstudy differences. Another study [82] investigating the interaction of smoking and two human leukocyte antigens (HLA-DR15 and HLA-A02) associated with MS, showed that smoking increased the MS risk by a factor of 2.8 in cases with both genetic risk factors in comparison with a factor of 1.4 in those without both genetic risk factors.
Next to EBV, vitamin D and exposure to sunlight are also important environmental risk factors associated with MS onset and perhaps even clinical course [83] [84] [85] [86] . More than 30 years ago, vitamin D deficiency was first proposed as a risk factor for MS. After discovery of the immunomodulatory effects of vitamin D [87, 88] , a role in MS susceptibility was warranted. Interestingly, lower serum levels of vitamin D and dietary intake of vitamin D in smokers have been reported in earlier studies [89] . An interaction between smoking and vitamin D has been suggested for rheumatoid arthritis [90] , however to our best knowledge this has not been demonstrated for MS [86] .
There is no lack of candidate mechanisms by which smoking could exert effects on susceptibility to MS as well as on the further clinical course. Different components of tobacco smoke have been discussed here. The suggestion that components of smoke play a role is also supported by a recent finding that even passive smoke exposure increases the MS risk [27] . Next to nitric oxide, which has putative roles in demyelination and axonal loss [42, 91] , some animal studies have suggested that smoke exposure affects several parts of the immune system, including innate immunity, B-and T-lymphocytes and natural killer cells [92, 93] . Other possible mechanisms have been suggested such as smoke induced (local) immunosuppression, with an associated increase in upper respiratory tract infections [94] .
In conclusion, the growing epidemiological evidence for an association between cigarette smoking and MS warrants further investigation with well-designed prospective studies. Animal models and basic research as well as ongoing large cohort studies will advance our understanding of mechanisms. This is important because understanding the role of smoking in the MS pathogenesis may enable us on one hand to temper disease onset and perhaps also control the clinical course in high risk individuals by putting a brake on exposure.
On the other hand it may provide fruitful insight for understanding MS pathogenesis and further development of therapeutical targets.
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